Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis (SEPT9-CROSS)
Diagnostic Accuracy of the Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection Among Cirrhotic Patients: the SEPT9-CROSS Study
Sponsor: Central Hospital, Nancy, France
A NA clinical study on Cirrhosis and Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Central Hospital, Nancy, France and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Feb 2025 — Sep 2025 [monthly]
Completed NA
Status: Unknown → Completed
-
Sep 2024 — Feb 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Jul 2022 — Jul 2024 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Jun 2022 — Jul 2022 [monthly]
Recruiting NA
-
Jan 2021 — Jun 2022 [monthly]
Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2020 [monthly]
Recruiting NA
-
Mar 2018 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2017 — Mar 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Central Hospital, Nancy, France
- Epigenomics, Inc
- Groupement Interrégional de Recherche Clinique et d'Innovation
- Institut National de la Santé Et de la Recherche Médicale, France
- New Day Diagnostics
For direct contact, visit the study record on ClinicalTrials.gov .